As of 2025-07-09, the Fair Value of Arbutus Biopharma Corp (ABUS) is -3.76 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 3.14 USD, the upside of Arbutus Biopharma Corp is -219.60%.
With the market price of 3.14 USD and our fair value calculation, Arbutus Biopharma Corp (ABUS) is not a good investment. Investing in Arbutus stocks now will result in a potential loss of 219.60%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -63.75 | -76.25 | -69.46 | -72.85 | -69.92 | -70.45 |
| YoY growth | 58.53% | -19.61% | 8.90% | -4.88% | 4.02% | 9.39% |
| Market Cap (mil) | 601.40 |
| P/E | |
| Forward P/E |
| EPS | -0.40 |
| Avg earnings growth rate | 9.39% |
| TTM earnings | -76.57 |